JP2020516264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516264A5 JP2020516264A5 JP2019555196A JP2019555196A JP2020516264A5 JP 2020516264 A5 JP2020516264 A5 JP 2020516264A5 JP 2019555196 A JP2019555196 A JP 2019555196A JP 2019555196 A JP2019555196 A JP 2019555196A JP 2020516264 A5 JP2020516264 A5 JP 2020516264A5
- Authority
- JP
- Japan
- Prior art keywords
- hbv
- immunogen
- viral vector
- expression cassette
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 36
- 229940023147 viral vector vaccine Drugs 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 108700024845 Hepatitis B virus P Proteins 0.000 claims 11
- 239000013603 viral vector Substances 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- 238000002255 vaccination Methods 0.000 claims 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 108010028930 invariant chain Proteins 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 102000004961 Furin Human genes 0.000 claims 1
- 108090001126 Furin Proteins 0.000 claims 1
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108700025184 hepatitis B virus X Proteins 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 208000007089 vaccinia Diseases 0.000 claims 1
- 229940126580 vector vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1705765.4 | 2017-04-10 | ||
| GBGB1705765.4A GB201705765D0 (en) | 2017-04-10 | 2017-04-10 | HBV vaccine |
| PCT/GB2018/050948 WO2018189522A1 (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516264A JP2020516264A (ja) | 2020-06-11 |
| JP2020516264A5 true JP2020516264A5 (enExample) | 2021-05-20 |
| JP7326157B2 JP7326157B2 (ja) | 2023-08-15 |
Family
ID=58744773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555196A Active JP7326157B2 (ja) | 2017-04-10 | 2018-04-10 | Ｈｂｖワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200113998A1 (enExample) |
| EP (1) | EP3609535B1 (enExample) |
| JP (1) | JP7326157B2 (enExample) |
| KR (1) | KR102700586B1 (enExample) |
| CN (2) | CN110913899B (enExample) |
| AU (1) | AU2018251241B2 (enExample) |
| CA (1) | CA3059290A1 (enExample) |
| DK (1) | DK3609535T3 (enExample) |
| ES (1) | ES3036962T3 (enExample) |
| GB (1) | GB201705765D0 (enExample) |
| MX (1) | MX2019012101A (enExample) |
| MY (1) | MY202396A (enExample) |
| PH (1) | PH12019502310A1 (enExample) |
| SG (1) | SG11201909353VA (enExample) |
| WO (1) | WO2018189522A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| US20220339281A1 (en) * | 2019-03-05 | 2022-10-27 | GalxoSmithKline Biologicals SA | Hepatitis b immunisation regimen and compositions |
| US20220305107A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| WO2020255055A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| CA3149415A1 (en) | 2019-08-29 | 2021-03-11 | Eric Bruening | Hepatitis b virus vaccines |
| EP4458975A3 (en) * | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| WO2021243149A2 (en) * | 2020-05-28 | 2021-12-02 | President And Fellows Of Harvard College | Protein covariance networks reveal interactions important to the emergence of sars coronaviruses as human pathogens |
| PH12023550030A1 (en) * | 2020-07-08 | 2024-03-11 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| JPWO2022071513A1 (enExample) | 2020-10-02 | 2022-04-07 | ||
| TW202245809A (zh) * | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| CN115595312A (zh) * | 2021-06-28 | 2023-01-13 | 中国农业大学（Cn） | 一种重组腺病毒及其应用 |
| US20250000968A1 (en) * | 2021-11-12 | 2025-01-02 | The United States of America, as represented by the Secretary,Department of Health and Human Service | Sars-cov-2 spike fused to a hepatitis b surface antigen |
| US20230310591A1 (en) | 2021-12-07 | 2023-10-05 | Vaccitech (Uk) Limited | Vaccine Boost Methods and Compositions |
| WO2024193905A1 (en) * | 2023-03-17 | 2024-09-26 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Hbv antigen formulation for treating hepatitis b |
| GB202317925D0 (en) | 2023-11-23 | 2024-01-10 | Spybiotech Ltd | Vaccines |
| CN118593695B (zh) * | 2024-08-07 | 2024-10-22 | 山东兴瑞生物科技有限公司 | 一种用于治疗HBV感染的siRNA和mRNA联合疫苗 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| CN101573449B (zh) * | 2006-08-14 | 2013-09-18 | 浦项工大产学协力团 | 用于治疗慢性乙型肝炎的dna疫苗及其制备方法 |
| NZ598000A (en) * | 2009-08-07 | 2013-10-25 | Transgene Sa | Composition for treating hbv infection |
| AP2013007110A0 (en) * | 2011-02-12 | 2013-09-30 | Globeimmune Inc | Yeast-based therapeutic for chronic hepatitis B infection |
| TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| CN103173492B (zh) * | 2013-03-12 | 2014-08-13 | 中国人民解放军白求恩国际和平医院 | 携带外源基因的复制型hbv载体、其转染后产生的重组hbv，和相应的制备方法与应用 |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
-
2017
- 2017-04-10 GB GBGB1705765.4A patent/GB201705765D0/en not_active Ceased
-
2018
- 2018-04-10 KR KR1020197031896A patent/KR102700586B1/ko active Active
- 2018-04-10 CN CN201880028408.6A patent/CN110913899B/zh active Active
- 2018-04-10 WO PCT/GB2018/050948 patent/WO2018189522A1/en not_active Ceased
- 2018-04-10 AU AU2018251241A patent/AU2018251241B2/en active Active
- 2018-04-10 JP JP2019555196A patent/JP7326157B2/ja active Active
- 2018-04-10 MY MYPI2019005911A patent/MY202396A/en unknown
- 2018-04-10 MX MX2019012101A patent/MX2019012101A/es unknown
- 2018-04-10 CA CA3059290A patent/CA3059290A1/en active Pending
- 2018-04-10 US US16/604,221 patent/US20200113998A1/en not_active Abandoned
- 2018-04-10 ES ES18719248T patent/ES3036962T3/es active Active
- 2018-04-10 EP EP18719248.9A patent/EP3609535B1/en active Active
- 2018-04-10 SG SG11201909353V patent/SG11201909353VA/en unknown
- 2018-04-10 DK DK18719248.9T patent/DK3609535T3/da active
- 2018-04-10 CN CN202410387306.0A patent/CN118576699A/zh active Pending
-
2019
- 2019-10-08 PH PH12019502310A patent/PH12019502310A1/en unknown
-
2023
- 2023-06-06 US US18/206,249 patent/US20240115694A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516264A5 (enExample) | ||
| JP7326157B2 (ja) | Ｈｂｖワクチン | |
| CN1180843C (zh) | 多表位疫苗 | |
| JP6702725B2 (ja) | 改良されたポックスウイルスワクチン | |
| EP2408473B1 (en) | Vaccination methods | |
| KR20180100228A (ko) | Hbv를 치료하기 위한 수단 및 방법 | |
| JP2014507146A5 (enExample) | ||
| JP2017522907A5 (enExample) | ||
| JP2005523318A5 (enExample) | ||
| JP2016510989A5 (enExample) | ||
| JP2003511010A (ja) | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 | |
| CA2683679A1 (en) | Adenoviral vector encoding malaria antigen | |
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| JP2020536489A5 (enExample) | ||
| RU2018122755A (ru) | Слитые белки fmdv-e2 и их применение | |
| WO2007119279A1 (ja) | コイヘルペスウイルス（ｋｈｖ）病用ｄｎａワクチン | |
| CN111741766A (zh) | 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物 | |
| JP2023528984A (ja) | コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン | |
| CN114375199A (zh) | 非洲猪瘟疫苗 | |
| AU2013339846B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
| JP2013512256A5 (enExample) | ||
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| KR20180017554A (ko) | 어류 바이러스성 출혈성 패혈증에 대한 예방 또는 치료용 dna 백신 | |
| CN102000330B (zh) | 一种核酸疫苗佐剂及其构建方法 | |
| JPWO2020065349A5 (enExample) |